Your browser doesn't support javascript.
loading
Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.
Raina, Komal; Kant, Rama; Prasad, Ram R; Kandhari, Kushal; Tomar, Munendra; Mishra, Neha; Kumar, Robin; Fox, Jennifer T; Sei, Shizuko; Shoemaker, Robert H; Chen, Yu; Maroni, Paul; Agarwal, Chapla; Agarwal, Rajesh.
Afiliación
  • Raina K; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Kant R; Department of Pharmaceutical Sciences, South Dakota State University, Brookings, South Dakota, USA.
  • Prasad RR; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Kandhari K; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Tomar M; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Mishra N; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Kumar R; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Fox JT; Department of Pharmaceutical Sciences, South Dakota State University, Brookings, South Dakota, USA.
  • Sei S; Division of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Shoemaker RH; Division of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Chen Y; Division of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Maroni P; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
  • Agarwal C; Department of Surgery, Division of Urology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Agarwal R; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Mol Carcinog ; 61(7): 717-734, 2022 07.
Article en En | MEDLINE | ID: mdl-35452553
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Adenocarcinoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Mol Carcinog Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Adenocarcinoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Mol Carcinog Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos